HK1022468A1 - Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors. - Google Patents

Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors.

Info

Publication number
HK1022468A1
HK1022468A1 HK00100870A HK00100870A HK1022468A1 HK 1022468 A1 HK1022468 A1 HK 1022468A1 HK 00100870 A HK00100870 A HK 00100870A HK 00100870 A HK00100870 A HK 00100870A HK 1022468 A1 HK1022468 A1 HK 1022468A1
Authority
HK
Hong Kong
Prior art keywords
beta
matrix metalloproteinases
hydroxamic acids
sulfonyl hydroxamic
metalloproteinases inhibitors
Prior art date
Application number
HK00100870A
Other languages
English (en)
Inventor
Martha A Warpehoski
Donald E Harper
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HK1022468A1 publication Critical patent/HK1022468A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
HK00100870A 1996-09-27 2000-02-14 Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors. HK1022468A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2684896P 1996-09-27 1996-09-27
PCT/US1997/016348 WO1998013340A1 (en) 1996-09-27 1997-09-19 β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS

Publications (1)

Publication Number Publication Date
HK1022468A1 true HK1022468A1 (en) 2000-08-11

Family

ID=21834136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00100870A HK1022468A1 (en) 1996-09-27 2000-02-14 Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors.

Country Status (22)

Country Link
US (2) US5847153A (de)
EP (1) EP0929519B1 (de)
JP (1) JP2001516338A (de)
KR (1) KR20000048639A (de)
CN (1) CN1158254C (de)
AT (1) ATE289590T1 (de)
AU (1) AU726799B2 (de)
BR (1) BR9712134A (de)
CA (1) CA2266368A1 (de)
CZ (1) CZ92399A3 (de)
DE (1) DE69732571T2 (de)
EA (1) EA001460B1 (de)
ES (1) ES2236829T3 (de)
HK (1) HK1022468A1 (de)
HU (1) HUP0000145A3 (de)
ID (1) ID21897A (de)
IL (1) IL128900A0 (de)
NO (1) NO312893B1 (de)
NZ (1) NZ334729A (de)
PL (1) PL332509A1 (de)
UA (1) UA48262C2 (de)
WO (1) WO1998013340A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69729007T2 (de) * 1996-08-07 2005-04-07 Darwin Discovery Ltd., Slough Hydroxamsäure- und carbonsäure-derivate mit mmp und tnf hemmender wirkung
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
CZ92399A3 (cs) 1996-09-27 1999-07-14 Pharmacia & Upjohn Company ß-sulfonylhydroxamové kyseliny jako inhibitory matriční metaloproteinázy
AU5337498A (en) 1997-01-22 1998-08-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted beta-thiocarboxylic acids
GB9702088D0 (en) 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
CN1253474A (zh) * 1997-03-04 2000-05-17 孟山都公司 磺酰基二价芳基或杂芳基异羟肟酸化合物
US6063786A (en) * 1997-11-12 2000-05-16 Darwin Discovery, Ltd. Heterocyclic compounds having MMP and TNF inhibitory activity
US6187924B1 (en) * 1997-11-12 2001-02-13 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
JP2001524462A (ja) 1997-11-21 2001-12-04 ファーマシア・アンド・アップジョン・カンパニー マトリックスメタロプロテイナーゼインヒビターとしてのβ−スルホニルヒドロキサム酸のα−ヒドロキシ、−アミノ及びハロ誘導体
PL200418B1 (pl) * 1998-01-30 2009-01-30 Darwin Discovery Ltd Pochodna N-hydroksyformamidu, zawierający ją środek farmaceutyczny i jej zastosowanie
EP0965592A1 (de) 1998-06-18 1999-12-22 F. Hoffmann-La Roche Ag Verfahren zur Herstellung von 3-Arylschwefel Hydroxamsäure
GB9916562D0 (en) 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
US6620823B2 (en) 2000-07-11 2003-09-16 Bristol-Myers Squibb Pharme Company Lactam metalloprotease inhibitors
GB0017435D0 (en) * 2000-07-14 2000-08-30 Pharmacia & Upjohn Spa 3-arylsulfonyl-2-hydroxy-2-methylpropanoic acid derivatives
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
WO2007070760A2 (en) * 2005-12-15 2007-06-21 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
EP2081905B1 (de) 2006-07-28 2012-09-12 Boehringer Ingelheim International GmbH Sulfonyl verbindungen als cb2 rezeptor modulatoren
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
EP2217565B1 (de) * 2007-11-07 2013-05-22 Boehringer Ingelheim International GmbH Cb2 rezeptor-modulierende verbindungen
US8178568B2 (en) 2008-07-10 2012-05-15 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the CB2 receptor
KR20110063438A (ko) * 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Ｃｂ2 수용체를 선택적으로 조절하는 설포닐 화합물
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
US8383615B2 (en) 2009-06-16 2013-02-26 Boehringer Ingelheim International Gmbh Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
JP5746228B2 (ja) 2010-03-05 2015-07-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節するテトラゾール化合物
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (de) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB689608A (en) * 1950-04-13 1953-04-01 Basf Ag Improvements in the production of gamma-sulphonyl carboxylic acids
US2659752A (en) * 1951-08-09 1953-11-17 Goodrich Co B F Method for preparing beta-(arylsulfonyl) carboxylic acids and salts thereof
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DE69309047T2 (de) * 1992-04-07 1997-09-11 British Biotech Pharm Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
DE4233100A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Sulfonylmethylpropionsäuren sowie Zwischenprodukte
DE4233099A1 (de) * 1992-10-01 1994-04-07 Hoechst Ag Verfahren zur stereoselektiven Synthese von 3-substituierten 2-Thiomethylpropionsäuren
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
EP0640594A1 (de) * 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoinderivat als Metalloproteaseinhibitor
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
DK0871439T3 (da) * 1996-01-02 2004-08-02 Aventis Pharma Inc Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
CZ92399A3 (cs) * 1996-09-27 1999-07-14 Pharmacia & Upjohn Company ß-sulfonylhydroxamové kyseliny jako inhibitory matriční metaloproteinázy
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds

Also Published As

Publication number Publication date
US6235928B1 (en) 2001-05-22
NZ334729A (en) 2001-01-26
CA2266368A1 (en) 1998-04-02
AU4645997A (en) 1998-04-17
WO1998013340A1 (en) 1998-04-02
BR9712134A (pt) 1999-08-31
US5847153A (en) 1998-12-08
KR20000048639A (ko) 2000-07-25
HUP0000145A2 (en) 2000-07-28
EP0929519A1 (de) 1999-07-21
ID21897A (id) 1999-08-05
UA48262C2 (uk) 2002-08-15
EA199900332A1 (ru) 1999-12-29
CN1230177A (zh) 1999-09-29
EP0929519B1 (de) 2005-02-23
ES2236829T3 (es) 2005-07-16
DE69732571T2 (de) 2006-01-12
ATE289590T1 (de) 2005-03-15
NO991494L (no) 1999-05-26
JP2001516338A (ja) 2001-09-25
PL332509A1 (en) 1999-09-13
DE69732571D1 (de) 2005-03-31
NO312893B1 (no) 2002-07-15
EA001460B1 (ru) 2001-04-23
CZ92399A3 (cs) 1999-07-14
HUP0000145A3 (en) 2001-12-28
NO991494D0 (no) 1999-03-26
IL128900A0 (en) 2000-01-31
CN1158254C (zh) 2004-07-21
AU726799B2 (en) 2000-11-23

Similar Documents

Publication Publication Date Title
HK1022468A1 (en) Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors.
CA2367017A1 (en) Inhibitors of impdh enzyme
IL143545A0 (en) Thrombin inhibitors
GR3035181T3 (en) Arylsulfonamido-substituted hydroxamic acids as matrix metalloproteinase inhibitors
ES2052452A1 (es) Procedimiento de preparacion de inhibidores duales de no-sintasa y ciclooxigenasa.
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
UA37181C2 (uk) ГІДРОХЛОРИД 7-<font face="Symbol">b</font>-[(Z)-2-(2-АМІНО-4-ТІАЗОЛІЛ)-3-ГІДРОКСИІМІНОАЦЕТА- МІДО]-3-(1,2,3-ТРИАЗОЛ-4-ІЛ)ТІОМЕТИЛТІО-3-ЦЕФЕМ-4-КАРБОНОВОЇ КИСЛОТИ АБО ЙОГО ГІДРАТИ, ЩО МАЮТЬ АНТИБАКТЕРІАЛЬНУ ДІЮ, ФАРМАЦЕВТИЧНА АНТИБАКТЕРІАЛЬНА КОМПОЗИЦІЯ, СПОСІБ ПРИГНІЧЕННЯ РОЗВИТКУ БАКТЕРІЙ, СПОСІБ ЛІКУВАННЯ БАКТЕРІАЛЬНИХ ІНФЕКЦІЙ
NO20003018D0 (no) Triazinangiogenese-inhibitorer
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
EA200101085A1 (ru) Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
AU5090393A (en) Platelet aggregation inhibitors
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
AU5710696A (en) Platelet aggregation inhibitors
NO983511L (no) Difenylstilbener som pro-legemidler til COX-2-inhibitorer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080919